Insulin delivery using an automated close-loop system significantly improves glycaemic control compared with conventional insulin injection among hospitalized patients with type 2 diabetes (T2D) receiving noncritical care, without increasing the risk of hypoglycaemia, according to a study presented at ADA 2018.
A novel formulation of the GLP-1* receptor agonist semaglutide in oral form led to clinically meaningful HbA1c reduction and weight loss at 26 weeks in patients with type 2 diabetes (T2D) uncontrolled on diet and exercise, according to the PIONEER-1** trial presented at ADA 2018.
The addition of the sodium-glucose linked transporter-2 inhibitor ipragliflozin to insulin resulted in more body weight and fat mass reduction as well as better glucose control than insulin alone in patients with type 2 diabetes (T2D) with weight gain issues, according to a Japanese trial presented at ADA 2018.
Individuals with diabetes who have experienced a recent episode of acute coronary syndrome (ACS) derive the greatest reduction in risk of subsequent major adverse cardiac events (MACE) when given a combination of the PCSK9* inhibitor alirocumab and high-intensity statins compared with individuals with prediabetes or normoglycaemia, according to results of the ODYSSEY OUTCOMES** trial.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.